Selective estrogen receptor modulators for preventing and treating postmenopausal osteoporosis
Editorial Group: Cochrane Musculoskeletal Group
Published Online: 20 FEB 2014
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
How to Cite
Li W, Zhang J, Xu L, Tang L, Pan X, Wu T. Selective estrogen receptor modulators for preventing and treating postmenopausal osteoporosis (Protocol). Cochrane Database of Systematic Reviews 2014, Issue 2. Art. No.: CD010977. DOI: 10.1002/14651858.CD010977.
- Publication Status: New
- Published Online: 20 FEB 2014
This is the protocol for a review and there is no abstract. The objectives are as follows:
To estimate the clinical benefits and harms of all SERMs for postmenopausal osteoporosis in both prevention (women without postmenopausal osteoporosis) and treatment (postmenopausal osteoporosis with or without clinical history of previous osteoporotic fractures).
The principle objective of this review is based on the following questions:
- Is the use of SERMs effective and safe for the prevention and treatment of postmenopausal osteoporosis?
- Are SERMs more effective and safer than other approved drugs for prevention and treatment of postmenopausal osteoporosis?
- Which type of SERMs is the most effective or safest?